Ravi Jahagirdar

Dr. Jahagirdar is the Vice President of Pharmacology, Toxicology, and Safety at Zenith and has led the team for lead drug candidate ZEN-3694 from discovery to IND. Ravi has more than 20 years of experience in both academia and industry in drug discovery and development. His area of expertise includes animal physiology, pharmacology, toxicology, DMPK, and basic research. He has been successful in recruiting scientists, building departments, and managing projects from early discovery to pre-clinical and clinical development. Ravi has also been with Resverlogix since 2004, playing a key role in all aspects of the development of apabetalone, including strategic leadership in the implementation of developmental toxicology and preclinical/clinical pharmacology. Ravi held previous positions of increasing responsibility at the University of Regina, and Tularik Inc. (Amgen).

Dr. Jahagirdar obtained his Doctor of Veterinary Medicine from Veterinary College, Bangalore, and an MS in Molecular Biology/Microbiology from Memorial University, Newfoundland. His research has been published in many peer-reviewed journals and has co-authored a textbook chapter and has numerous abstract presentations.